The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MRUS | +77.48% | +622.82% | +48.53% | +840% |
| S&P | +14.5% | +93.32% | +14.09% | +228% |
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.
This biotech's second experimental cancer drug to begin clinical trials produced some encouraging results.
With Breast Cancer Awareness Month drawing to a close and the San Antonio Breast Cancer Symposium on the horizon, stay alert for breaking news from companies developing new treatments.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $8.83M | 20.4% |
| Gross Profit | $8.19M | 0.0% |
| Gross Margin | 92.81% | 0.0% |
| Market Cap | $3.92B | 0.0% |
| Market Cap / Employee | $15.07M | 0.0% |
| Employees | 260 | 13.5% |
| Net Income | -$158.22M | -216.2% |
| EBITDA | -$109.72M | -72.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $442.79M | -29.7% |
| Accounts Receivable | $16.89M | 816.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $8.75M | -6.2% |
| Short Term Debt | $2.25M | 33.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -41.18% | -14.5% |
| Return On Invested Capital | -45.67% | 1.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$75.72M | -1853.6% |
| Operating Free Cash Flow | -$75.62M | -1406.6% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.86 | 4.09 | 4.47 | 6.10 | -38.58% |
| Price to Sales | 94.90 | 80.10 | 53.08 | 66.51 | -36.04% |
| Price to Tangible Book Value | 4.87 | 4.10 | 4.48 | 6.12 | -38.70% |
| Enterprise Value to EBITDA | -38.95 | -26.87 | -32.68 | -27.71 | -38.74% |
| Return on Equity | -44.6% | -42.9% | -58.7% | -48.5% | 45.36% |
| Total Debt | $11.05M | $9.91M | $9.86M | $11.00M | -0.19% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
